Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis

Next Previous
Trial Profile

Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Baricitinib (Primary) ; Etanercept (Primary) ; Filgotinib (Primary) ; Infliximab (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Upadacitinib (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GISEA

Most Recent Events

  • 03 Jun 2023 Results (n=1361) of a descriptive analysis assessing long-term retention rate of JAKis and influence of baseline population characteristics on treatment persistence presented at the 24th Annual Congress of the European League Against Rheumatism
  • 01 Oct 2021 Results (n=278) assessing the effectiveness and drug retention rate of a second-line biologic therapy with TNFi or other MoA, after switching from a first-course treatment with either RTX, TCZ, or ABA in RA patients, published in the Clinical Rheumatology.
  • 27 Sep 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top